Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
|Videos|August 24, 2017
Treat-to-Target in Rheumatoid Arthritis
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
As pharmaceutical markets become increasingly dynamic, health systems may benefit from shifting toward unit-level economic frameworks that evaluate cost and margin performance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
4
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
5